US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

Parabilis Medicines, Inc. (PBLS): Regeneron Validation Powers Parabilis Toward Public Markets

Parabilis Medicines, Inc. (PBLS): IPO Prices Above Range, Opens with Massive First-Day Pop

Parabilis Medicines, Inc. (PBLS): Peeking at the IPO Prospectus of a Peptide Therapeutic Company

IPOs and Secondary Offerings

Equity Capital Markets

Parabilis Medicines / Equity Capital Markets

<ul>
<li>Parabilis Medicines IPO sets terms at $17–$19 for 25M shares, supported by a $75M strategic investment from Regeneron Pharmaceuticals, signaling strong validation.</li>
<li>Clinical-Stage biotech targeting historically undruggable proteins via Helicon platform; lead asset zolucatetide shows strong early efficacy in desmoid tumors, including 74% objective response rate.</li>
<li>Pipeline expands into oncology targets ERG and ARON, with venture-backed ownership; IPO expected to draw specialized biotech and crossover investors in a “clubby” book.</li>
</ul>


Parabilis Medicines IPO sets terms at $17–$19 for 25M shares, supported by a $75M strategic investment from Regeneron Pharmaceuticals, signaling strong validation.
Clinical-Stage biotech targeting historically undruggable proteins via Helicon platform; lead asset zolucatetide shows strong early efficacy in desmoid tumors, including 74% objective response rate.
Pipeline expands into oncology targets ERG and ARON, with venture-backed ownership; IPO expected to draw specialized biotech and crossover investors in a “clubby” book.


Parabilis Medicines, Inc. (PBLS): Biotech Targeting Desmoid Tumor Sets Terms for IPO